Public Company News

FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura

YONGIN, South Korea, Oct. 5, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura (TTP), received an Orphan Drug Designation onSeptember 27 from the U.S. Food and Drug Administration (FDA). When designated as an orphan...

2023-10-06 08:12 3166

WiMi Proposed UAV Controlled Brain-computer Interface System Based on Semi-autonomous Navigation and Motor Imagery

BEIJING, Oct. 5, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that a brain-computer interface (BCI) system control method based on electroencephalography (EEG) is pro...

2023-10-05 20:00 3300

NaaS Technology Became the First Batch of Strategic Enterprises of OASES of HK Special Administrative Region

BEIJING, Oct. 4, 2023 /PRNewswire/ -- On October 4th, NaaS Technology Inc. (NASDAQ: NAAS) reached a strategic partnership with Office for Attracting Strategic Enterprises (OASES) of Hong Kong Special Administrative Region (HKSAR) and thereby became the first batch of strategic enterprises of OASE...

2023-10-05 11:05 6345

Antelope Enterprise Holdings Regains Compliance with NASDAQ Minimum Bid Price Requirement

CHENGDU, China, Oct. 4, 2023 /PRNewswire/ -- Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) ("Antelope Enterprise" or the "Company"), which operates KylinCloud, a livestreaming ecommerce business in China with access to 400,000+ hosts and influencers, announced today that on O...

2023-10-04 21:30 6141

KREAM Announces Business Integration with SODA... To Leap as Asia's Largest C2C and Fashion E-commerce Platform

* SODA, Operator of Japan's Largest Limited-Edition Goods Trading Platform SNKRDUNK, is Leading the Country's Consumer Trend and Culture * Integration of the two companies is expected to create the number one C2C and fashion e-commerce platform in theAsia-Pacific region, beyond Korea and Ja...

2023-10-04 21:00 3835

WiMi is Reaching Feature Transformation Technique for Image Data Augmentation

BEIJING, Oct. 4, 2023 /PRNewswire/––WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that WiMi is working on feature transformation technique for image data augmentation, which is a commonly ...

2023-10-04 20:00 2351

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...

2023-10-04 08:00 2233

Infortrend Announces a Strategic Value-Added Distribution Partnership for the South Asia Region Enterprise Storage Market with Supertron VAD

TAIPEI, Oct. 3, 2023 /PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, today announced the signing o...

2023-10-03 23:00 2050

Innovative International Acquisition Corp. and Zoomcar, the World's Largest Emerging Market Focused Car Sharing Platform, Announce Effectiveness of Registration Statement on Form S-4, Date of IOAC's Extraordinary General Meeting to Approve Proposed Business Combination, Zoomcar Written Consent Solicitation

* Extraordinary general meeting of IOAC shareholders scheduled for October 25, 2023, to vote on the proposed business combination of IOAC with Zoomcar * Zoomcar is the world's leading emerging market peer2peer car sharing platform with operations acrossIndia, Indonesia and Egypt * Zoomcar an...

2023-10-03 21:39 6755

First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial

SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...

2023-10-03 20:58 2755

WiMi Developed a Machine Learning-based Multi-modal Fusion Recommendation System

BEIJING, Oct. 3, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that a multi-modal fusion recommendation system based on machine learning is developed to provide users ...

2023-10-03 20:00 2202

WeTrade Group Inc. Announces Filing of A Derivative Lawsuit Against Former Officers and Directors

BEIJING, Oct. 3, 2023 /PRNewswire/ -- WeTrade Group Inc. ("WETG" or the "Company") (NASDAQ: WETG) today(October 3, 2023) announced that on September 28, 2023, a derivative lawsuit was filed in the United States District Court for the District ofWyoming against Biming Guo, Ning Qin, Yuxing Ye, Hec...

2023-10-03 19:30 2481

China Yuchai Subsidiary Wins an Order for 20MW Ferroalloy Off-Gas Power Generation

SINGAPORE, Oct. 3, 2023 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD)("China Yuchai" or the "Company") a leading manufacturer and distributor of engines through its main operating subsidiary inChina, Guangxi Yuchai Machinery Company Limited ("GYMCL"), today announced that GYMCL's...

2023-10-03 18:30 6538

FIRST Global, Title Sponsor Lam Research to Host the World's Most International Innovation Challenge to Inspire Kids in STEM, Future Solutions for Climate Change

BANDAR CASSIA, Malaysia, Oct. 3, 2023 /PRNewswire/ -- The 2023 FIRST Global Challenge will in a few weeks bring together thousands of teens from across the globe to compete in robotics and collaborate to find renewable energy solutions. Created and administered byFIRST Global and helped made poss...

2023-10-03 06:00 2394

Jianpu Technology Inc. Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price

BEIJING, Oct. 2, 2023 /PRNewswire/ -- Jianpu Technology Inc. ("Jianpu" or the "Company") (NYSE: JT), a leading independent open platform for discovery and recommendation of financial products inChina, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") date...

2023-10-03 05:00 7032

Boqii Holding Limited Announces Transfer to NYSE American

SHANGHAI, Oct. 2, 2023 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE: BQ), a leading pet-focused platform inChina, announced today that it will transfer the listing of its American Depositary Shares from the New York Stock Exchange to NYSE American LLC ("NYSE American"). ...

2023-10-03 04:08 6353

Aetherium Announces Receipt of Nasdaq Notice of Additional Delinquency

GREENWICH, Conn., Oct. 2, 2023 /PRNewswire/ -- Aetherium Acquisition Corp ("Company") (Nasdaq: "GMFI") today announced, as expected, that onAugust 23, 2023, the Company received an additional delinquency notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock M...

2023-10-03 04:03 5507

VEDU Symbol Changes

TORONTO, Oct. 2, 2023 /PRNewswire/ -- Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ: VEDU), aprivate education provider located inCanada, with subsidiaries in Canada and market partners in China, today announced that it will be changing its ticker symbol from "VEDU" t...

2023-10-03 04:00 5597

Cheche Group Providing Insurance Services for Xpeng EVs in Ten Cities

BEIJING, Oct. 2, 2023 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced its growing partnership withXpeng, Inc. (NYSE: XPEV) ("Xpeng"), a l...

2023-10-02 21:00 6297

Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study

- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...

2023-10-02 21:00 2092
1 ... 391392393394395396397 ... 766